3,5-Diiodo-l-thyronine ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats  by Shang, Guoguo et al.
Biochimica et Biophysica Acta 1832 (2013) 674–684
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad is3,5-Diiodo-L-thyronine ameliorates diabetic nephropathy in
streptozotocin-induced diabetic rats☆,☆☆Guoguo Shang 1, Pan Gao 1, Zhonghua Zhao, Qi Chen, Tao Jiang, Nong Zhang, Hui Li ⁎
Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, People's Republic of ChinaAbbreviations: T2, 3,5-diiodothyronine; T3, triiodoth
Silent Information Regulator Transcript 1; HG, high
NF-κB, nuclear factor-κappa B; JNK, c-Jun N-terminal ki
type IV collagen; TGF-β1, transforming growth factor b
DN, diabetic nephropathy
☆ This study was supported by grants from the Nation
of China (NSFC 30900538).
☆☆Disclosure statement: The authors have nothing to
⁎ Corresponding author. Tel.: +86 21 5423 7528; fax
E-mail address: huili78@fudan.edu.cn (H. Li).
1 Guoguo Shang and Pan Gao contributed equally to
0925-4439/$ – see front matter © 2013 Elsevier B.V. Al
http://dx.doi.org/10.1016/j.bbadis.2013.01.023a b s t r a c ta r t i c l e i n f oArticle history:
Received 19 October 2012
Received in revised form 13 January 2013
Accepted 29 January 2013
Available online 8 February 2013
Keywords:
3, 5-Diiodothyronine
Diabetic nephropathy
Mesangial cells
SIRT1
NF-κB
JNK3, 5-Diiodothyronine (T2), a natural metabolite of triiodothyronine (T3) from deiodination pathway, can
mimic biologic effects of T3 without inducing thyrotoxic effects. Recent studies revealed T3 acted as a protec-
tive factor against diabetic nephropathy (DN). Nevertheless, little is known about the effect of T2 on DN. This
study was designed to investigate whether and how T2 affects experimental models of DN in vivo and in
vitro. Administration of T2 was found to prevent signiﬁcant decrease in SIRT1 protein expression and activity
as well as increases in blood glucose, urine albumin excretion, matrix expansion, transforming growth
factor-β1 expression, ﬁbronectin and type IV collagen deposition in the diabetic kidney. Concordantly, similar
effects of T2 were exhibited in the cultured rat mesangial cells (RMC) exposed to high glucose and that could
be abolished by a known SIRT1 inhibitor, sirtinol. Moreover, enhanced NF-κB acetylation and JNK phosphor-
ylation present in both diabetic rats and high glucose-treated RMC were distinctly dampened by T2. Collec-
tively, these results suggested that T2 was a protective agent against renal damage in diabetic nephropathy,
whose action involved regulation of SIRT1.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Diabetic nephropathy (DN) is themost common cause of end-stage
renal disease in the world, and accounts for a signiﬁcant increase in
morbidity and mortality in patients with diabetes. Current therapies
directed at delaying the progression of DN includes strict glycemic
and optimal blood pressure control, proteinuria/albuminuria reduc-
tion, interruption of the renin–angiotensin–aldosterone system, along
with dietary modiﬁcation and cholesterol lowering agents. However,
the renoprotection provided by these conventional treatments is
incomplelte, calling for more innovative strategies and effective ap-
proaches [1].
Thyroid hormones (THs) play a vital role in differentiation, growth,
and metabolism and are required for the normal function of nearly all
tissues. There are primarily two biologically active thyroid hormones:
thyroxine (T4) and triiodothyronine (T3). THs exert most of their ef-
fects through TH receptors (TRs). However, some effects of THs cannot
be explained by a TRs-dependent pathway but can be ascribed to someyronine; T4, thyroxine; SIRT1,
glucose; NG, normal glucose;
nases; FN, ﬁbronectin; COL IV,
eta 1; RMC, rat mesangial cell;
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l rights reserved.of the TH derivatives via a non TRs-dependent pathway [2]. 3,
5-diiodothyronine (T2), a putative product of the deiodination path-
way involved in T3 metabolism, mimics several biologic effects of T3
without inducing thyrotoxic effects [3]. There is increasing recognition
that there are links between thyroid and kidney function in pathological
conditions [4]. Recently, Y. Lin et al. demonstrated that T3 administra-
tion prevented progressive kidney damage in a mouse model of type II
diabetes [5]. The present studywas implemented to determinewhether
T2 has protective effect against the development and progression of DN
models in vivo and in vitro and explore the related mechanisms.
2. Materials and methods
All chemicals and antibodies were obtained from Sigma-Aldrich
Company (St. Louis, MO, USA) and Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA), respectively, unless otherwise stated.
2.1. Animals
Male Sprague–Dawley (SD) rats ranging from 8 to 10 weeks old,
with initial body weights of ~200 g were purchased from by the
Shanghai SLAC Laboratory Animal Center. The animals were housed
under standard laboratory conditions of 21±2 °C, relative humidity
of 55% and 12 h:12 h light:dark cycle were maintained during the
study. The animals were given standard rat pellets and tap water ad
libitum. All experimental protocols followed the Criteria of theMedical
Laboratory Animal Administrative Committee of Shanghai and the
Guide for Care and Use of Laboratory Animals of Fudan University. All
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number of animals used.
2.2. Experimental groups
Diabetes mellitus (DM) was induced by intraperitoneal injection of
streptozotocin (STZ) at 60 mg/kg body weight into overnight-fasted
rats. Rats received solvent of STZ, i.e., 0.01 citrate buffer (pH 5.5) alone,
as the control group. Three days after STZ injection, blood samples
were collected through the tail vein and blood glucose levels were
measured. Rats with blood glucose levels ≥300 mg/dL were con-
sidered diabetic. STZ-DM rats were randomly divided into 3 groups
(n=9 in each group): one group without any treatment, the other
two groups were treated with T2 or an equal volume of saline as pla-
cebo, respectively. T2 was administered daily through intraperitoneal
injection at 0.25 mg/kg for 12 weeks [3]. Blood glucose level and body
weight were monitored throughout the course of treatment. At the
end of 12 weeks of treatment, rats were put into clean metabolic cages
one day before sacriﬁce, and urine was collected for 24 h. Overnight-
fasted ratswere anesthetizedwith intraperitoneal pentobarbital sodium
(30 mg/kg body weight) and their kidneys were dissected promptly.
Blood samples were harvested via an intracardiac needle using a chilled
syringe containing 10 IU heparin and centrifuged at 13,000 rpm for
10 min at 4 °C. The plasma was stored at−80 °C prior to further use.
Themiddle third of the right kidney from each rat was ﬁxed in 4% para-
formaldehyde and embedded in parafﬁn for morphology evaluation
and immunohistochemistry analysis. The renal cortex of the left kidney
and residual right kidney from each rat was immediately frozen in
liquid nitrogen and stored at−80 °C for later processing.
2.3. Measurements of blood glucose and 24 h-urine
Blood glucose level was determined by glucometer (Ascensia Elite,
Bayer, Leverkusen, Germany). Total protein, creatinine and albumin
in urine were detected by standard diagnostic kits (Jiancheng Biotech
Co., Ltd., Nanjing, China) according to the manufacturer's instructions.
2.4. Renal morphology assessment
Tissue sections from parafﬁn-embedded kidneys were stained
with hematoxylin-eosin (H&E), periodic acid Schiff (PAS), andMasson's
trichrome. Images were captured by Axiocam camera system (Zeiss,
New York, USA). Glomerulosclerotic index was assessed on PAS-stained
tissue sections using a ﬁve-grade method described previously [6].
In brief, forty glomeruli in each kidney were graded in accordance
with their severity of glomerular damage (0, normal; 1, slight glo-
merular damage, the mesangial matrix and/or hyalinosis with focalTable 1
DN, diabetic nephropathy; T2, 3, 5-diiodothyronine. Streptozotocin-induced diabetic rats
12 weeks.
Group Control
n 9
Body weight, g 501.9±20.3
Kidney weight, mg 1958.9±75.5
Kidney weight/body weight ratio, mg/g 3.9±0.2
Blood glucose, mmol/L 5.3±0.2
Total urine protein (mg/24 h) 8.3±0.3
Urine albumin, μg/dL 6.0±0.3
Urine creatinine, mg/dL 0.29±0.02
Urine albumin/creatinine ratio μg/mg 21.1±1.5
All data are expressed as mean±stand errors (SEM).
★ Pb0.05 vs. normal control group.
▲ Pb0.05 vs. diabetic nephropathy group.
# Pb0.05 vs. saline-treated diabetic nephropathy group.adhesion involving b25% of the glomerulus; 2, sclerosis of 26–50%; 3,
sclerosis of 51–75%; and 4, sclerosis of >75% of the glomerulus). The
glomerulosclerotic indexeswere calculated using the following formula:
glomerulosclerotic index=(1×n1)+(2×n2)+(3×n3)+(4×n4)/
n0+n1+n2+n3+n4, where nx is the number of glomeruli in each
grade of glomerulosclerosis. For Masson's trichrome stain, areas of
collagen deposition was analyzed by measuring the percentage area
of blue staining under 400-fold magniﬁcation using computer-assisted
image analysis software (I-Solution, Image & Microscope Technology
Corporation, Vancouver, BC, Canada). Nine rats per groupwere counted
and an average score was calculated for each group. All sections were
examined without knowledge of treatment.
2.5. Immunohistochemistry analysis
Immunohistochemistry analysis was performed to evaluate TGF-β1,
ﬁbronectin, collagen IV and SIRT1 expression. After deparafﬁnization
and trypsinization, sections were washed in Tris-buffered saline (TBS;
10 mmol/L Tris−HCl, 0.85% NaCl, pH 7.5) containing 0.1% bovine
serum albumin (BSA). Endogenous peroxidase activity was quenched
by incubating the slides in methanol and 0.3% H2O2/methanol. After
3 washes in TBS, the samples were incubated for 1 h at 37 °C in 4%
BSA-5% normal horse serum to block nonspeciﬁc binding sites, and
then reacted with the primary antibody (TGF-β1 1:400, ﬁbronectin
1:500, collagen IV 1:1000, SIRT1 1:1000) at 4 °C overnight. Negative
control sections had the omission of the primary antibody. The sections
were then washed in TBS 3 times, and HRP conjugated secondary anti-
body (Santa Cruz) was added and incubated at room temperature for
45 min. The immunostaining was visualized using diaminobenzidine
tetrahydrochloride (DAB), and the slides were counterstained with
hematoxylin. Immunoreactivity in the sections was analyzed by mea-
suring the percentage area of positive staining under 400-fold magniﬁ-
cation using computer-assisted image analysis software (I-Solution,
Image & Microscope Technology Corporation, Vancouver, BC, Canada).
For all sections, 25 random ﬁelds were examined per section. Nine ani-
mals per group were counted and then averaged to derive an average
score for each group. Results were expressed as proportional area of
positive staining.
2.6. Cell culture
The rat glomerularmesangial cell linewas purchased fromAmerican
Type Culture Collection (RMC, ATCC number CRL-2573) and cultured in
normal DMEM medium (5.5 mM D-glucose, NG) supplemented with
10% neonatal bovine serum in an atmosphere of 95% O2 and 5% CO2 at
37 °C. High glucose (HG) culture medium was made by supplementing
normal DMEM medium with additional D-glucose for a ﬁnal D-glucosewere treated with T2 (0.25 mg/kg, intraperitoneal injection, daily) or without T2 for
DN DN+saline DN+T2
9 9 9
268.8±11.3★ 281.6±13.5★ 428.1±16.8▲,#
3862.2±138★ 3917.8±159.3★ 2468.9±108.6▲,#
13.6±0.6★ 14.3±1.1★ 6.1±0.2▲,#
22.1±1.0★ 20.9±1.7★ 6.3±0.3▲,#
52.7±3.1★ 57±2.3★ 13.5±0.7▲,#
29.7±1.8★ 31.5±1.5★ 20.7±0.9▲,#
0.27±0.01 0.25±0.01 0.303±0.02
108.3±5.8★ 124.5±8.9★ 68.4±2.7▲,#
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supplementing normal medium with 24.5 mM mannitol. The cultured
mesangial cells at about 70–80% conﬂuence were cultured in serum-
free DMEM with NG for 24 h to synchronize the cell growth. After that,
the medium was replaced with fresh serum-free medium containing
NG alone, NG plus mannitol, HG alone, HG plus T2 (100 μM), HG plus
T2 (100 μM) and SIRT1 inhibitor Sirtinol(10 μM) for 1 h [7] (protein
phosphorylation and deacetylation detection) or 24 h stimulation.
2.7. Isolation of total RNA and quantitative real-time PCR
Cultured RMC or renal cortex was lysed in TRIZOL reagent and
total RNA was isolated. The amount of RNA isolated was determined
by measuring the speciﬁc absorbance at 260 nm. Aliquots of 40 ng
of each total RNA samples were subjected to one-step real-time
RT-PCR using a QuantiTect SYBR Green RT-PCR kit (Qiagen, Santa
Clarita, CA) and Rotor-Gene RG-3000A apparatus (Corbett Research,Fig. 1. Histopathological changes in the kidneys of diabetic rats with or without T2 treatmen
Each image is a representative of nine kidney tissue sections from nine rats in each group. Or
C. Proportional area of ﬁbrosis for various groups as indicated. PAS and Masson's trichrome s
Data are represented as mean±SEM (n=9). ★Pb0.05 vs. NC. ▲Pb0.05 vs. DN. #Pb0.05 vs.Sydney, Australia). Each reaction mix contained the following: 40 ng
RNA, 100 ng of each primer, 12.5 μl 2×PCR buffer, 0.5 μl RT mix, and
DEPC-H2O to 25 μl. The following conditions were used: for reverse
transcription, 30 min at 50 °C; for the PCR initial activation step,
15 min at 95 °C; and for ampliﬁcation, 15 s at 94 °C, 30 s at 56 °C,
and 30 s at 72 °C for 25 cycles. Changes in the mRNA expression level
were calculated following normalization with β-actin. Primers used
for gene ampliﬁcation are listed as follows: SIRT1 (sense: 5′-AGACAA
CCTCCTGTTGGCTGATGA-3′, antisense: 5′-TCACTAGAGCTTGCGTGTG
ATGCT-3′, 95 bp product); ﬁbronectin (sense: 5′-AACAAATCTCCTG
CCTGGGACTGA-3′, antisense: 5′-TGAGTTGGCGGTGACATCAGAAGA-3′
145 bp product); collagen IV (sense: 5′- CCCCTGTAAGACACCATTAGC-
3′, antisense: 5′-AGCACCCAGTTTAGTTGTCC-3′ 128 bp product); TGFβ1
(sense: 5′-CCTGAGTGGCTGTCTTTTGA-3′, antisense: 5′- CGTGGAGTACA
TTATCTTTGCTG-3′ 100 bp product); β-actin (sense: 5′-CTGAACCCCAA
AGCCAAC-3′, antisense: 5′-CACCATCACCAGAGTCCATCAC-3′, 148 bp
product).t. A. Kidney tissue sections were subject to H&E, PAS and Masson's trichrome staining.
iginal magniﬁcation ×400. B. Glomerulosclerosis index for different groups as indicated.
taining were determined semiquantitatively as described under Materials and methods.
DN+saline.
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For immunoblot analysis, renal cortex of the frozen kidneys was
homogenized in lysis buffer (0.1 mol/L Tris buffer [pH 7.4], 0.1 mmol/L
EDTA) in the presence of 1 mmol/L dithiothreitol, 1 mmol/L phenyl-
methylsulfonyl ﬂuoride, and a protease inhibitor cocktail (Roche, USA).
Cells grown in a 100-mm culture dish were lysed at 4 °C in lysis buffer
(10 mM Tris/HCl, pH7.5, 150 mM NaCl, 1% Nonidet P-40) containing
protease inhibitors (1 mM phenylmethylsulfonyl ﬂuoride, 1 mM EDTA,
1 μg/mL leupeptin, 1 μg/mL pepstain, 1 μg/mL aprotinin). Protein con-
centrations of the samples were measured by the bicinchoninic acid
(BCA) method. To determine the protein levels of TGF-β1, ﬁbronectin,Fig. 2. Expression of ﬁbronectin, collagen IV, TGF-β1 and SIRT1 in the kidneys of diabetic r
collagen IV, TGF-β1 and SIRT1 in the kidneys of different groups as indicated horizontally
TGF-β1, and SIRT1 immunostaining in the kidneys of different groups as indicated. Data
.DN+saline.collagen IV, SIRT1, acetylated-NF-κB, phosphorylated-JNK, renal cortex
lysate or cultured RMC lysatewere separated by sodium dodecyl sulfate
(SDS) polyacrylamide gel electrophoresis (Bio-Rad, CA, USA) and
transferred electrophoretically to nitrocellulose membranes. The
membranes were then blocked with 5% non-fat dried milk or 5% bo-
vine serum albumin in Tris buffered saline Tween (20 mM Tris
pH 7.6, 137 mM NaCl, and 0.1% Tween 20). The primary antibodies
against TGF-β1, collagen IV and acetylated-NF-κB were obtained from
Abcam (Cambridge, MA, USA), those against SIRT1, β-actin and
phosphorylated-JNK were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA), and those against ﬁbronectin were obtained
from Calbiochem (San Diego, California, USA); the antibodies wereats with or without T2 treatment. A. Immunohistochemical photograph of ﬁbronectin,
. Original magniﬁcation ×400. B. Semiquantitative analysis of ﬁbronectin, collagen IV,
are represented as mean±SEM (n=9),★Pb0.05 vs. NC. ▲Pb0.05 vs. DN. #Pb0.05 vs
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1:500(SIRT1, TGFβ1, collagen IV, phosphorylated-JNK). The membrane
was incubated overnight at 4 °C with the primary antibody, and the
bound antibody was visualized using the respective horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology
Inc.) and chemiluminescence developing agents (Amersham
Biosciences, Buckinghamshire, UK). The levels of β-actin were esti-
mated in every sample to ensure the equal loading of the samples. The
bands of western blotting were quantiﬁed by densitometry measure-
ment using gene tools from Syngene.2.9. Assessment of SIRT1 activity
Tomeasure SIRT1 deacetylase activity, Cyclex SIRT1/Sir2 Deacetylase
Fluorometric Assay Kit (Cyclex, CY-1151) was used according to the
established protocol, including the separation of nuclear extract. In
brief, nuclear extracts (10 μl) were mixed with a reaction mixture
(40 μl) containing 50 mM Tris–HCl pH 8.8, 4 mM MgCl2, 0.5 mM DTT,
0.25 mA U/mL lysyl endpeptidase, 1 μM trichostatin A, 20 μM ﬂuoro-
substrate peptide, and 200 μM NAD+ in a microplate and incubated
for10 min at room temperature. Fluorescence intensity was read in
clear, half-volume 96-well plates on SpectraMAX Gemini XS ﬂuores-
cence plate reader (excitation 355 nm, emission 465 nm, gain=85).
Calculation of net ﬂuorescence was obtained by subtraction of the
blank control value from the quadruplicate mean of each samples ﬂuo-
rescence readings and normalized by the protein content.Fig. 3. Effect of T2 on mRNA level of ﬁbronectin, collagen IV, TGF-β1, and SIRT1 in the kidne
SIRT1 (D) were measured by real time PCR. The data are relative mRNA level normalized to
DN. #Pb0.05 vs. DN+saline.2.10. Statistical analysis
All data are expressed as mean±standard errors (SEM). Analysis
of variance (ANOVA)was used to assess the differences betweenmulti-
ple groups. If the F statistics were signiﬁcant, the mean values obtained
from each groupwere then compared by Fisher's least signiﬁcant differ-
ence method. P value b0.05 was used as the criterion for a statistically
signiﬁcant difference.
3. Results
3.1. T2 improves renal functions in diabetic rats
To evaluate the renal hypertrophy and renal dysfunction, ratio of
kidney weight/bodyweight and ratio of urine albumin/urine creatinine
(UACR) was measured, respectively. Diabetic rats showed a noticeable
increment of ratio of kidney weight/body weight (13.6±0.6 mg/g,
Pb0.05 versus normal group) and UACR (108.3±5.8 μg/mg, Pb0.05
versus normal group). Treatment with T2 markedly lowered the ratio
of kidney weight/body weight (6.1±0.2 mg/g, Pb0.05 versus diabetic
group) and UACR (68.4±2.7 μg/mg, Pb0.05 versus diabetic group)
(Table 1.).
3.2. T2 ameliorates renal histopathologic changes in diabetic rats
Renal histopathologic changes were determined by H&E, PAS, and
Masson's trichrome staining. H&E-stained diabetic kidney tissuesys of diabetic rats. The mRNA levels of ﬁbronectin (A), collagen IV (B), TGF-β1 (C) and
β-actin mRNA level and presented as mean±SEM (n=9). ★Pb0.05 vs. NC. ▲Pb0.05 vs.
Fig. 4. Effect of T2 on protein level of ﬁbronectin, collagen IV, TGF-β1, and SIRT1 as well as SIRT1 activity in the kidneys of diabetic rats. Representative Western blots and densi-
tometric analysis of ﬁbronectin (A), collagen IV (B), TGF-β1 (C) and SIRT1 (D). Each lane contained total proteins from kidneys of all the rats in each group. Western blot data were
normalized to an internal control (β-actin) and presented as mean±SEM (n=4). (E) The graphical representation of SIRT1 activity. ★Pb0.05 vs. NC. ▲Pb0.05 vs. DN. #Pb0.05 vs.
DN+saline.
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Fig. 5. Effect of T2 on mRNA level of ﬁbronectin, collagen IV, TGF-β1, and SIRT1 in the high glucose-treated RMC. The mRNA levels of ﬁbronectin (A), collagen IV (B), TGF-β1 (C) and
SIRT1 (D) were measured by real time PCR. The data are relative mRNA level normalized to β-actin mRNA level and presented as mean±SEM from four independent experiments.
★Pb0.05 vs. NG. ▲Pb0.05 vs. HG. #Pb0.05 vs. HG+T2.
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sules, constricted capillaries and expanded mesangial regions, which
were scarcely observed in kidneys of control rats. PAS staining showed
much more glycogen deposition in kidneys of diabetic group than in
those of control group. Masson's trichrome staining revealed that colla-
gens deposition was heavy in kidneys of diabetic rats while slight in
those of control rats. All these renal histopathologic changes shown in
diabetic rats were obviously alleviated in T2-treated diabetic rats.
Semi-quantitative analysis of PAS and Masson's trichrome stained
kidney tissues consistently indicated the beneﬁcial effects of T2 on DN
(Fig. 1).
3.3. T2 reduces TGF-β1, ECM deposition and concomitantly increases
SIRT1 expression and activity in diabetic rats
As SIRT1 is recently proposed as a novel therapeutic target for DN
and TGF-β1 is recognized as a key proﬁbrotic cytokine in DN [8,9],
we assessed ECM accumulation, TGF-β1and SIRT1 expression, with
immunohistochemistry, real time RT-PCR and Western blot analysis.
T2 exhibited an inhibitory effect on increasedmRNAandprotein expres-
sion of TGF-β1, ﬁbronectin and collagen IV in the diabetic group asmea-
sured by immunohistochemical examination (Fig. 2), real-time-PCR
(Fig. 3) and Western blot analysis (Fig. 4). Furthermore, Western blot
and SIRT activity analysis revealed that T2 diminished reduction ofFig. 6. Effect of T2 on protein level of ﬁbronectin, collagen IV, TGF-β1, and SIRT1 as well as
sitometric analysis of ﬁbronectin (A), collagen IV (B), TGF-β1 (C) and SIRT1 (D). Western bl
from four independent experiments. (E) The graphical representation of SIRT1 activity. ★PSIRT1expression and activity in the diabetic group (Fig. 4). However,
SIRT1 mRNA level showed no difference among groups, suggesting
the decline of SIRT1 protein expression in the diabetic group was not
caused by decreased transcription (Fig. 3).
3.4. T2 attenuates high glucose-induced upregulation of TGF-β1, type IV
collagen and ﬁbronectin expression as well as downregulation of SIRT1
expression and activity in cultured rat mesangial cells
In vitro, HG (30 mM D-glucose) caused a remarkable increase of
TGF-β1, ﬁbronectin and collagen IV expression at both mRNA (Fig. 5)
and protein levels (Fig. 6). Moreover, Western blot and SIRT1 activity
analysis (Fig. 6) showed amarked drop of SIRT1 expression and activity
in HG group compared with NG (5.6 mM D-glucose) and isotonic man-
nitol (5.6 mM D-glucose+24.4 mM D-mannitol) group, which exclud-
ed the possibility that the alterations described above were mediated
by high osmotic pressure. Addition of T2 counteracted HG-induced
increase of TGF-β1, ﬁbronectin and collagen IV expression as well as
decrease of SIRT1 expression and activity. As an inhibitor, sirtinol
induced a blockade of SIRT1 activity concomitantwith amild repression
of SIRT1 protein expression. In the presence of sirtinol, T2 was not able
to activate SIRT1 and did not prevent HG-mediated TGF-β1, ﬁbronectin
and collagen IV overexpression. These results suggested an essential
role of SIRT1 in the renoprotective effect of T2 (Fig. 6).SIRT1 activity in the high glucose-treated RMC. Representative Western blots and den-
ot data were normalized to an internal control (β-actin) and presented as mean±SEM
b0.05 vs. NG. ▲Pb0.05 vs. HG. #Pb0.05 vs. HG+T2.
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in both diabetic rats and high glucose-treated rat mesangial cells
Since SIRT1 is known to interfere with the NF-kappaB signaling
pathway as a deacetylase and JNK phosphorylation is linked to degra-
dation of SIRT1 [10,11], we observed the inﬂuence of high glucose on
the level of NF-κB acetylation and JNK phosphorylation in vivo and in
vitro with Western blot analysis. Our in vivo and in vitro ﬁndings
demonstrated that HG promoted NF-κB acetylation and JNK phos-
phorylation, which was substantially inhibited by T2 treatment
(Fig. 7). Sirtinol had no effect on the T2-inhibited JNK phosphoryla-
tion but reversed T2-suppressed NF-κB acetylation. These results
indicated that T2-decreased NF-κB acetylation was dependent on
SIRT1 while T2-weakened JNK phosphorylation was independent of
SIRT1. Our data also showed that T2 depressed JNK phosphorylation,
together with a restoration of SIRT1 expression. This led to speculation
that T2 might modulate SIRT1 expression via regulating JNK phos-
phorylation. Next, we will further examine this supposition with
inhibitors of JNK phosphorylation.4. Discussion
As both DM and thyroid diseases involve endocrine impairment
and autoimmune disorders it is no wonder that frequency of thyroid
dysfunction in diabetic patients is two times higher than that in the
general population [12]. Manifest hypothyroidism leads to a decrease
in insulin sensitivity and thus impairs glucose homeostasis. These
changes are reversible by substitution [13–15]. Thyroxine (T4) and
triiodo-L-thyronine (T3) are conventionally regarded as the only thy-
roid hormones able to inﬂuence energy metabolism and thus efﬁcient-
ly attenuate DM and DM-related abnormalities [5,16,17]. However,
several observations recently revealed that iodothyronines other than
T3 possess biological activity, leading to a reconsideration of this idea
[18]. Among natural metabolites, 3,5-diiodothyronine (T2) has been
shown to be bioactive and can mimic some effects of T3. More impor-
tantly, T2 has been demonstrated to exert effects similar to that of T3
without inducing a thyrotoxic state which strongly limits the use of
T4 and T3 [3]. Therefore, it is attractive and meaningful to investigate
the potential therapeutic role of T2 for preventing DM and its compli-
cations. Some studies lately have provided insight into the ability of
T2 to counteract high-fat-diet-induced insulin resistance [19,20]. How-
ever, the effect of T2 on diabetic kidney disease has not been explored
yet.
The present study is the ﬁrst report elucidating the renoprotective
effect of T2 in experimental DN. T2-treated diabetic animals exhibited
a signiﬁcantly ameliorated albuminuria, glomerular hypertrophy and
kidney tissue expression of TGF-β1, type IV collagen and ﬁbronectin.
Given that hyperglycemia may be involved in the development of
DN and that T2 decreased blood glucose levels in diabetic rats in
our experiment, the anti-hyperglycemic effect of T2 may contribute
to its protective effects on DN. M. Moreno et al. reported that T2
restored growth hormone (GH) level in hypothyroid rats [21]. STZ
treatment was found to blunt not only insulin synthesis but also GH
secretion [22]. Growing evidence shows that GH plays an important
role in regulation of blood glucose hemostasis [23–25]. Thus, we pos-
tulated that T2exerted hypoglycemic effects in our animal experiment
via ameliorating STZ-ablated GH production. Certainly, this hypothesis
needs to be tested by further studies. On the other hand, strict glyce-
mic control does not completely stop the progression of DN in diabetic
patients clinically and our results showed the beneﬁcial effects of T2
on key ﬁbrogenic cytokine TGF-β1 and matrix molecules such as type
IV collagen and ﬁbronectin were also presented in mesangial cells ex-
posed to sustaining high glucose stimulation in vitro. These results
imply that there are other mechanisms underlying the salutary actions
of T2 in DN.Sirtuin 1 (SIRT1) is a member of the sirtuin family of histone
deacetylases whose activities are induced by nicotinamide adenine di-
nucleotide (NAD+). Histone acetyltransferase and histone deacetylase
are enzymes responsible for histone acetylation and deacetylation,
respectively, in which the histones are acetylated and deacetylated
on lysine residues in the N-terminal tail and on the surface of the nucleo-
some core. These processes are considered themost important epigenetic
mechanisms for remodeling the chromatin structure and controlling gene
expression. In general, histone acetylation promotes gene activation,
whereas histone deacetylation results in gene repression. Numerous
studies revealed that many pathogenic gene expressions were in-
creased via acetylation of core histones aroundwounded DNA and con-
versely switching off these abnormally activated genes by deacetylation
of related histones may become an innovative treatment target [26].
SIRT1 deacetylates not only histone proteins but also various tran-
scription factors like p53, FOXOs and NF-kB. The powerful ability of
deacetylation makes SIRT1 implicated in the regulation of various
physiological functions including cell death, stress tolerance, insulin
resistance, fat metabolism and inﬂammation [27]. Our data indicated
that SIRT1 was downregulated in parallel with upregulation of TGF-β1,
type IV collagen and ﬁbronectin expression in vivo and in vitro. Accord-
ingly, T2 improved renal structure and function, together with restoring
SIRT1 expression in diabetic rats. These results suggested T2 ameliorated
DN via normalization of SIRT1expression. In agreement with our data,
many other studies indicate that preservation of SIRT1 expression is a
promising strategy for treating DN [28–30]. In our study, T2-improved
SIRT1 activity is correlated with T2-elevated SIRT1 expression, implying
that T2 raised SIRT1 activity at least partially through enhancing SIRT1
expression. Nevertheless, it is reported by P. De Lange et al. that T2
also can directly activate SIRT1 independently from regulating SIRT1
expression [19].
NF-κB is a family of transcription factors that are usually present
as dimers, the most common being the p50/p65 heterodimer. Activa-
tion of NF-κB results from the dissociation of inactive heterodimeric
complexes from their inhibitory subunit (IκB) in the cytoplasm and
translocation of the active NF-κB complexes (p50/p65) to the nucleus.
NF-kB dependent on transcription of genes such as TGF-β1, monocyte
chemoattractant protein-1 (MCP-1) and ﬁbronectin contributes to
diabetic renal injury [31]. Recently, it has been documented that
acetylation of p65 enhances the DNA-binding activity of NF-kB and
impairs its association with the inhibitor I kB. By contrast, deacetylation
of p65 by SIRT1 inactivates NF-kB and thus terminates NF-kB-
dependent gene expression [32]. In our present study, T2 markedly
attenuated the increase in NF-kB p65 acetylation as well as TGF-β1,
type IV collagen and ﬁbronectin expression, which in vitro could be
totally blocked by sirtinol. These results hinted that T2 might affect
these NF-kB-associated genes via deacetylation regulation of NF-kB
activity.
Though increasing studies showed a drop of SIRT1 expression in
DN [28–30], the relative mechanism is still unclear. Among the nu-
merous signaling pathways implicated in the pathogenesis of diabetes
and renal injury, c-Jun N-terminal kinases (JNK) have been the subject
of intense interest due to their pivotal role in metabolic conditions
and renal pathophysiology [33]. Thus targeting of JNK inactivation is
of critical signiﬁcance in diabetes and renal disease therapy. Recently,
Z. Gao et al. suggested that persistent JNK1 activation leads to inhibi-
tion of SIRT1 activity through extensive protein degradation [11]. Our
in vivo and in vitro experiments consistently revealed that the level
of JNK phosphorylation was much higher in diabetic groups compared
to that in normal counterparts, which is parallel with decreased SIRT1
protein expression. By contrast, T2 treatment attenuated JNK phos-
phorylation and retained SIRT1 protein expression in diabetic models,
which implicated inactivation of JNK in mechanisms of T2 preserving
SIRT1 protein expression in DN.
In conclusion, ourworkﬁrstly provides evidence that T2 can amelio-
rate renal damage in experimental models of DN. Sirtinol, the speciﬁc
Fig. 7. Effect of T2 on NF-κB acetylation and JNK phosphorylation in the kidneys of diabetic rats and high glucose-treated RMC. Representative Western blots (upper panel) showing
speciﬁc bands for acetylated NF-κB in vivo (A) and in vitro (C) as well as phosphorylated JNK in vivo (B) and in vitro (D). Each lane contained total proteins from the kidneys of all
the rats in the group as indicated or proteins of RMC cultured in the conditions as indicated. The intensity of the bands was analyzed densitometrically (lower panel) and corrected
for β-actin levels. Results represent four experiments conducted in quadruplicate. ★Pb0.05 vs. NC or NG. ▲Pb0.05 vs. DN or HG. #Pb0.05 vs. DN+saline or HG+T2.
683G. Shang et al. / Biochimica et Biophysica Acta 1832 (2013) 674–684inhibitor of SIRT1, can abolish the beneﬁcial effect of T2 in vitro,
suggesting that SIRT1 plays a crucial role in the renoprotective action
of T2. Future research should further explore themechanismsunderlying
the regulatory effect of T2 on SIRT1, thereby leading to a better under-
standing of therapeutic potential of T2 for diabetes and its complications.Acknowledgments
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